Repros Therapeutics Inc. (NASDAQ:RPRX) gained 57.74% up to $1.09 on news Repros received guidance from  the Division of Reproductive and Urologic Products of the FDA on January 25th, 2010. The focus of the teleconference meeting was to know the FDA’s current position regarding the use of Repros’ oral Androxal for the treatment of men with secondary hypogonadism while preserving fertility. The company’s data supports the notion that the negative feedback of exogenous testosterone administered by any route suppresses the hypothalamic–pituitary axis and causes spermatogenesis. The FDA requested a label to better identify individuals Repros believes will benefit from the use of Androxal. The FDA also requested a review of the literature of the incidence of infertility associated with the use of exogenous testosterone as supportive of the Repros’ data.  If the FDA is satisfied by the submission, there will be no more additional clarifying meetings regarding Androxal. Based in The Woodlands, Texas, Repros Therapeutics is a development-stage biopharmaceutical company developing drug therapies for the treatment of serious female pelvic conditions, such as treatment of uterine fibroids, anaemia associated with excessive menstrual bleeding relating to uterine fibroids, and anaemia associated with uterine fibroids and endometriosis.  Repros Therapeutics has three late stage drug candidates in trials including Androxal, a hormone treatment of for low testosterone levels in men.  RPRX is surging on heavy volume with 9,850,267 shares moving actively, and is trading well above its 50 day moving average of $0.74.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Related posts:

1. BSDM, RPRX Jump In Morning Trading BSDM up 45.51% on news the Journal of the National...
2. Repros Stock Surges On Positive Trial Results Repros Therapeutics Inc. skyrocketed 124.73% on news disclosed late yesterday,...
3. QLTI Jumps On Settlement QLT will pay $20 million to the Massachusetts General Hospital...
4. Biotech And Biopharmaceutical Solutions Make Strong Gains In Late Morning Pro-Dex, Inc. jumped 27.66% boasting gross profits for the quarter...
5. HDIX Acquired By Nipro Corp For $215 million, Stock Skyrockets 89 Percent Home Diagnostics supplies to the rapidly growing $7 billion diabetes...

Related posts brought to you by Yet Another Related Posts Plugin.